14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
EMR vs ABBNY: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Emerson Electric Co. (EMR) is the stronger overall head-to-head candidate over ABBNY (ABBNY) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). EMR carries a Unified Composite Score of 51.2/100 (HOLD) at $161.06 (22.9x Forward P/E, 24.8% operating margin), whereas ABBNY carries 55.7/100 (HOLD) at $83.75 (N/M Forward P/E, N/A operating margin).
Composite vs. Pillar Nuance: While ABBNY currently prints a higher short-term Unified Composite Score (55.7/100 HOLD vs. EMR 51.2/100 HOLD), EMR captures the overall institutional head-to-head verdict (9–1 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (24.8% vs. N/A operating margin) and revenue trajectory (+7.1% vs. N/A YoY).
Technical & Structure Timing Caution: EMR trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 46.2); meanwhile ABBNY is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 41.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on EMR vs ABBNY. Trailing 12-month operating profitability (EMR 24.8% vs ABBNY N/A) and valuation multiples (EMR 22.9x vs ABBNY N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ EMR vs ABBNY Key Questions & Quantitative Answers
As of Nov 16, 2026, Emerson Electric Co. (EMR) is the stronger overall head-to-head candidate over ABBNY (ABBNY) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). EMR carries a Unified Composite Score of 51.2/100 (HOLD) at $161.06 (22.9x Forward P/E, 24.8% operating margin), whereas ABBNY carries 55.7/100 (HOLD) at $83.75 (N/M Forward P/E, N/A operating margin). Composite vs. Pillar Nuance: While ABBNY currently prints a higher short-term Unified Composite Score (55.7/100 HOLD vs. EMR 51.2/100 HOLD), EMR captures the overall institutional head-to-head verdict (9–1 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (24.8% vs. N/A operating margin) and revenue trajectory (+7.1% vs. N/A YoY). Technical & Structure Timing Caution: EMR trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 46.2); meanwhile ABBNY is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 41.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
EMR leads the Growth & Scale pillar: EMR posts +7.1% YoY revenue growth and +23.8% YoY earnings growth on $19.0B TTM revenue (52.7% gross margin, 24.8% operating margin), compared with ABBNY at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, EMR generates $19.0B in USD-normalized revenue versus N/A for ABBNY. In operating R&D and SG&A reinvestment, EMR deploys 27.9% of Rev ($5.30B) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ABBNY.
EMR screens cheaper on headline valuation multiples. EMR trades at 22.9x Forward P/E, 34.9x Trailing P/E, 2.02x PEG, and 5.4x EV/Revenue (18.6% FCF margin), whereas ABBNY trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against EMR (13.1% ROE) versus ABBNY (N/A ROE) capital efficiency.
In options market volatility and institutional positioning, EMR carries 46.6% implied volatility (6th %ile, Compressed (<25th %ile)), a 0.40x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.45β · 34% Vol realized risk). By comparison, ABBNY carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.81β · 41% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.